Sign In

Login

Password

Forgot Password ? Sign Up

Moxonidin (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Moxonidin" in Czech language version.

refsWebsite
Global rank Czech rank
7nih.gov
4th place
8th place
7worldcat.org
5th place
3rd place

nih.gov

ncbi.nlm.nih.gov

  • KARLAFTI, E. F.; HATZITOLIOS, A. I.; KARLAFTIS, A. F., et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci.. 2013, roč. 5, čís. 4, s. 253–6. Dostupné online. ISSN 0976-4879. 
  • PARATI, G.; ESLER, M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J.. 2012, roč. 33, čís. 9, s. 1058–66. Dostupné online. ISSN 1522-9645. 
  • EDWARDS, L. P.; BROWN-BRYAN, T. A.; MCLEAN, L., et al. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther.. 2012, roč. 30, čís. 4, s. 199–208. Dostupné online. ISSN 1755-5922. 
  • RÖSEN, P.; OHLY, P.; GLEICHMANN, H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens Suppl.. 1997, roč. 15, čís. 1, s. S31-8. Dostupné online. ISSN 0952-1178. 
  • HAUSBERG, M.; TOKMAK, F.; PAVENSTÄDT, H., et al. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens.. 2010, roč. 28, čís. 9, s. 1920–7. Dostupné online. ISSN 1473-5598. 
  • AMANN, K.; GREBER, D.; GHAREHBAGHI, H., et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens.. 1992, roč. 5, čís. 2, s. 76–83. Dostupné online. ISSN 0895-7061. 
  • SCHACHTER, M.; LUSZICK, J.; JÄGER, B., et al. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf.. 1998, roč. 19, čís. 3, s. 191–203. Dostupné online. ISSN 0114-5916. 

worldcat.org

  • KARLAFTI, E. F.; HATZITOLIOS, A. I.; KARLAFTIS, A. F., et al. Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection. J Pharm Bioallied Sci.. 2013, roč. 5, čís. 4, s. 253–6. Dostupné online. ISSN 0976-4879. 
  • PARATI, G.; ESLER, M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J.. 2012, roč. 33, čís. 9, s. 1058–66. Dostupné online. ISSN 1522-9645. 
  • EDWARDS, L. P.; BROWN-BRYAN, T. A.; MCLEAN, L., et al. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther.. 2012, roč. 30, čís. 4, s. 199–208. Dostupné online. ISSN 1755-5922. 
  • RÖSEN, P.; OHLY, P.; GLEICHMANN, H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens Suppl.. 1997, roč. 15, čís. 1, s. S31-8. Dostupné online. ISSN 0952-1178. 
  • HAUSBERG, M.; TOKMAK, F.; PAVENSTÄDT, H., et al. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens.. 2010, roč. 28, čís. 9, s. 1920–7. Dostupné online. ISSN 1473-5598. 
  • AMANN, K.; GREBER, D.; GHAREHBAGHI, H., et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens.. 1992, roč. 5, čís. 2, s. 76–83. Dostupné online. ISSN 0895-7061. 
  • SCHACHTER, M.; LUSZICK, J.; JÄGER, B., et al. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf.. 1998, roč. 19, čís. 3, s. 191–203. Dostupné online. ISSN 0114-5916.